$849 Million is the total value of Consonance Capital Management LP's 20 reported holdings in Q2 2017. The portfolio turnover from Q1 2017 to Q2 2017 was 50.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AMRN | Sell | AMARIN CORP PLCspons adr new | $100,042,000 | +24.8% | 24,824,280 | -0.9% | 11.79% | +40.3% |
| GMED | Sell | GLOBUS MED INCcl a | $93,980,000 | +8.1% | 2,835,000 | -3.4% | 11.07% | +21.5% |
| MYGN | Buy | MYRIAD GENETICS INC | $84,432,000 | +47.7% | 3,267,487 | +9.8% | 9.95% | +66.1% |
| AAAP | Buy | ADVANCED ACCELERATOR APPLICsponsored ads | $72,986,000 | +39.6% | 1,869,507 | +42.5% | 8.60% | +56.9% |
| PTCT | New | PTC THERAPEUTICS INC | $72,330,000 | – | 3,946,009 | +100.0% | 8.52% | – |
| ATRC | Sell | ATRICURE INC | $69,093,000 | +25.0% | 2,849,185 | -1.3% | 8.14% | +40.5% |
| CORT | Buy | CORCEPT THERAPEUTICS INC | $68,491,000 | +20.9% | 5,804,340 | +12.3% | 8.07% | +35.9% |
| LJPC | Buy | LA JOLLA PHARMACEUTICAL CO | $59,913,000 | +41.3% | 2,012,519 | +41.7% | 7.06% | +58.8% |
| CLVS | Sell | CLOVIS ONCOLOGY INC | $51,014,000 | -40.0% | 544,843 | -59.2% | 6.01% | -32.5% |
| KERX | New | KERYX BIOPHARMACEUTICALS INC | $50,646,000 | – | 7,005,041 | +100.0% | 5.97% | – |
| RTRX | Buy | RETROPHIN INC | $47,283,000 | +20.1% | 2,438,540 | +14.4% | 5.57% | +35.1% |
| CVRS | CORINDUS VASCULAR ROBOTICS I | $28,114,000 | +42.0% | 15,114,872 | 0.0% | 3.31% | +59.7% | |
| SPPI | New | SPECTRUM PHARMACEUTICALS INC | $15,053,000 | – | 2,020,583 | +100.0% | 1.77% | – |
| PACB | New | PACIFIC BIOSCIENCES CALIF IN | $13,644,000 | – | 3,832,713 | +100.0% | 1.61% | – |
| VCEL | Sell | VERICEL CORP | $8,468,000 | +1.4% | 2,566,084 | -14.0% | 1.00% | +14.1% |
| ANIP | ANI PHARMACEUTICALS INC | $6,693,000 | -5.5% | 143,003 | 0.0% | 0.79% | +6.3% | |
| ADMA | ADMA BIOLOGICS INC | $4,714,000 | -24.2% | 1,273,933 | 0.0% | 0.56% | -14.9% | |
| BIOL | Sell | BIOLASE INC | $1,118,000 | -34.4% | 1,152,737 | -8.6% | 0.13% | -25.8% |
| SPNE | Sell | SEASPINE HLDGS CORP | $618,000 | -10.7% | 53,627 | -39.1% | 0.07% | 0.0% |
| SBBP | STRONGBRIDGE BIOPHARMA PLC | $72,000 | +50.0% | 10,000 | 0.0% | 0.01% | +60.0% | |
| ARRY | Exit | ARRAY BIOPHARMA INC | $0 | – | -1,373,471 | -100.0% | -1.29% | – |
| ACOR | Exit | ACORDA THERAPEUTICS INC | $0 | – | -619,419 | -100.0% | -1.36% | – |
| ACHC | Exit | ACADIA HEALTHCARE COMPANY IN | $0 | – | -310,666 | -100.0% | -1.42% | – |
| NVDQ | Exit | NOVADAQ TECHNOLOGIES INC | $0 | – | -3,018,179 | -100.0% | -2.46% | – |
| PCRX | Exit | PACIRA PHARMACEUTICALS INC | $0 | – | -972,535 | -100.0% | -4.65% | – |
| MNKKQ | Exit | MALLINCKRODT PUB LTD CO | $0 | – | -1,558,944 | -100.0% | -7.28% | – |
| UTHR | Exit | UNITED THERAPEUTICS CORP DEL | $0 | – | -642,168 | -100.0% | -9.11% | – |
| HZNP | Exit | HORIZON PHARMA PLC | $0 | – | -6,218,903 | -100.0% | -9.63% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITED THERAPEUTICS CORP DEL | 29 | Q2 2022 | 15.9% |
| ADMA BIOLOGICS INC | 27 | Q4 2020 | 2.3% |
| RETROPHIN INC | 23 | Q1 2020 | 11.3% |
| ANI PHARMACEUTICALS INC | 23 | Q3 2019 | 7.9% |
| VERICEL CORP | 21 | Q4 2019 | 5.5% |
| AMARIN CORP PLC | 14 | Q3 2019 | 14.4% |
| GLOBUS MED INC | 13 | Q2 2022 | 24.7% |
| ORTHOFIX INTL N V | 13 | Q3 2016 | 9.7% |
| PACIFIC BIOSCIENCES CALIF IN | 13 | Q4 2018 | 9.7% |
| CATALYST PHARM PARTNERS INC | 13 | Q3 2019 | 9.4% |
View Consonance Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Surrozen, Inc./DESold out | December 15, 2022 | 0 | 0.0% |
| ADMA BIOLOGICS, INC. | February 14, 2022 | 1,289,481 | 1.4% |
| ASSEMBLY BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| CASI Pharmaceuticals, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Cellectar Biosciences, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Gamida Cell Ltd.Sold out | February 14, 2022 | 0 | 0.0% |
| GenMark Diagnostics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Protagonist Therapeutics, IncSold out | February 14, 2022 | 0 | 0.0% |
| Sio Gene Therapies Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Consonance-HFW Acquisition Corp. | April 27, 2021 | 1,000,000 | 10.4% |
View Consonance Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2022-12-15 |
| SC 13D/A | 2022-12-15 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
View Consonance Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.